@entity230 represent the only pharmacological palliative treatment for @entity1555 . However, they do have side effects and despite a large number of published studies showing their efficacy, they are still not universally used. This is largely due to the lack of functional outcome and quality of life measures in most of the published studies and suggests that further trials might be required to answer some of the still unclear aspects of their role. Another important aspect of @entity134 therapy in @entity1555 is that we do not know how they work in @entity121 . We have initiated a collaborative study on gene profiling using microarray in @entity134 -treated mdx @entity19 . cDNA microarray studies were performed to examine the levels of skeletal muscle gene expression in a pool of mdx @entity19 treated with @entity617 for 1 and 6 weeks. Interesting preliminary data on untreated mdx @entity19 suggest that the gene profiling of young (7 weeks) versus older (12 weeks) @entity19 is very significantly different. Furthermore, a large number of genes showed significant changes in expression at the mRNA level on treatment with @entity617 . These included structural protein genes; signalling genes and genes involved in immune response. Hopefully, analysis of this pattern of @entity134 -induced gene expression will provide some insight into understanding how glucocorticoids improve strength in @entity1555 , and may help in developing more effective and less toxic therapeutic approaches.

@entity230 in XXXX : from clinical trials to genomic research.

@entity19 :: ('10090', 'Species') :: ['mice'] @entity1555 :: ('MESH:D020388', 'Disease') :: ['Duchenne dystrophy', 'Duchenne muscular dystrophy'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity230 :: ('MESH:D013256', 'Chemical') :: ['Steroids'] @entity121 :: ('MESH:D009135', 'Disease') :: ['dystrophic muscle'] @entity617 :: ('MESH:D011239', 'Chemical') :: ['prednisolone']
@entity1555 :: (MESH:D020388,Disease) :: ['Duchenne muscular dystrophy']
